ClinicalTrials.gg
CompletedNCT00901186RED-ESUpdated Mar 3, 2017Results posted

Efficacy and Safety of Ranibizumab (Intravitreal Injections) Versus Laser Treatment in Patients With Visual Impairment Due to Diabetic Macular Edema

A Phase 2 interventional study of RFB002 and Laser photocoagulation in Diabetic Macular Edema and Visual Impairment, sponsored by Novartis Pharmaceuticals. Completed at 17 sites in Spain. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2017-03-03.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
83
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 26 studies testing ranibizumab in Vision Disorders — none open to participants now, none under way, none of them phase 3. Ranibizumab · Vision Disorders.

Enrollment
21st of 26
83 · median 178
Started
2009
the only one that year
Phase 2
3 of 26
none open now
Registered
4th of 26
by date
Lead sponsor
20 of 26
Novartis Pharmaceuticals

Among the 26 studies testing ranibizumab in Vision Disorders, this one is the 21st largest by enrollment, is the only one that started in 2009, is one of 3 in phase 2, and was the 4th registered.

Vision Disorders

361 studies on the registry are indexed under Vision Disorders; 85 are open to participants now.

Browse Vision Disorders studies →

Open to participants now

None of the 26 studies testing ranibizumab in Vision Disorders is open now. The open studies under Vision Disorders, anywhere →

About ranibizumab

Ranibizumab: first FDA approval 2006 (LUCENTIS), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 46 Vision Disorders studies recruiting now, 21 (46%) set no upper age limit and 16 (35%) stop at 75 or younger; 18 take children under 18; 13 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 26 studies testing ranibizumab in Vision Disorders as a file.
02

Study summary

This study will assess the efficacy and safety of ranibizumab (intravitreal injections) versus laser treatment in patients with visual impairment due to diabetic macular edema.

03

Conditions studied

  • Diabetic Macular Edema
  • Visual Impairment

Browse trials for

Keywords

  • Diabetic Macular Edema
  • Ranibizumab
  • Laser Treatment
  • Visual impairment
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Diabetes mellitus 1 or 2, \< 11.0%, With: Diabetic Macular Edema in at least one eye.
  2. Previous treatment with macular photocoagulation only should be considered if the investigator believes that the study eye may possibly benefit from additional photocoagulation.
  3. Best corrected visual acuity score between 78 and 25 letters (Early Treatment Diabetic Retinopathy Study- ETDRS Chart - 4 meters).
  4. Central foveal thickness >250µm (Optical Coherence Tomography).
  5. Diabetes medication stable in the 3 months prior.

Exclusion criteria

Exclusion Criteria:

In the study eye:

  1. Active intraocular inflammation.
  2. Any active infection.
  3. History of uveitis.
  4. Structural damage within 500 microns of the center of the macula.
  5. Neovascularization of the iris.
  6. Uncontrolled glaucoma in either eye (Intraocular Pressure > 24 mmHg).

Other protocol-defined inclusion/exclusion criteria may apply.

Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
83 participants (actual)

Study arms

  • Experimental
    RFB002

    RFB002 0.5 mg was administered to the study eye with a single monthly intravitreal injection on day 1, day 30 and day 60. After day 90, if stable vision was not achieved, a monthly injection of RFB002 0.5 mg was administered until stable vision was achieved.

    Drug: RFB002

  • Active comparator
    Laser photocoagulation

    At least one treatment of laser photocoagulation was applied on day 1. The maximum number of laser photocoagulation treatments was 4.

    Procedure: Laser photocoagulation

Interventions

  • DrugRFB002

    0.5 mg

    Also known as: Ranibizumab

  • ProcedureLaser photocoagulation
06

What researchers measure

Primary outcomes

  1. Mean Change From Baseline in Best Corrected Visual Acuity (BCVA)

    Visual acuity (VA) was assessed on the study eye during every study visit using best correction determined from protocol refraction. VA measurements were performed with the patient in a sitting position using Early Treatment Diabetic Retinopathy Study (ETDRS)-like visual acuity testing charts at a testing distance of 4 meters.

    Time frame: Baseline, 12 months

Secondary outcomes

  1. Percentage of Participants With Improvement in BCVA

    Visual acuity (VA) was assessed on the study eye during every study visit using best correction determined from protocol refraction. VA measurements were performed with the patient in a sitting position using Early Treatment Diabetic Retinopathy Study (ETDRS)-like visual acuity testing charts at a testing distance of 4 meters.

    Time frame: 12 months

  2. Evolution of Mean Change From Baseline in BCVA by Study Visit

    Visual acuity (VA) was assessed on the study eye during every study visit using best correction determined from protocol refraction. VA measurements were performed with the patient in a sitting position using Early Treatment Diabetic Retinopathy Study (ETDRS)-like visual acuity testing charts at a testing distance of 4 meters.

    Time frame: Baseline, Months 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12

  3. Percentage of Participants With VA > 73 Letters With Ranibizumab (0.5 mg) vs Laser.

    VA score was based on the number of letters read correctly on the Early Treatment Diabetic Retinopathy Study (ETDRS) visual acuity chart assessed at a starting distance of 4 meters.

    Time frame: 12 months

  4. Mean Change From Baseline in Central Retinal Thickness (CRT) by Study Visit

    CRT was assessed by Optical Coherence Tomography (OCT).

    Time frame: Baseline, Months 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12

  5. Percentage of CRT Change From Baseline by Study Visit

    CRT was assessed by Optical Coherence Tomography (OCT).

    Time frame: Baseline, Months 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12

07

Results

Posted Jul 3, 2014

Participant flow

Participant flow — Overall Study
MilestoneRFB002Laser Photocoagulation
Started4043
Safety set3943
Intent to treat3538
Completed3132
Not completed911
Withdrew: Lack of efficacy01
Withdrew: Abnormal laboratory values01
Withdrew: Lost to follow-up20
Withdrew: Adverse event24
Withdrew: Administration problems01
Withdrew: Protocol deviations54

Outcome measures

PrimaryMean Change From Baseline in Best Corrected Visual Acuity (BCVA)

Visual acuity (VA) was assessed on the study eye during every study visit using best correction determined from protocol refraction. VA measurements were performed with the patient in a sitting position using Early Treatment Diabetic Retinopathy Study (ETDRS)-like visual acuity testing charts at a testing distance of 4 meters.

Time frame:
Baseline, 12 months
Reported as:
Mean · letters
Mean Change From Baseline in Best Corrected Visual Acuity (BCVA)
lettersRFB002Laser Photocoagulation
Mean Change From Baseline in Best Corrected Visual Acuity (BCVA)9.41 ± 9.155.79 ± 9.40
SecondaryPercentage of Participants With Improvement in BCVA

Visual acuity (VA) was assessed on the study eye during every study visit using best correction determined from protocol refraction. VA measurements were performed with the patient in a sitting position using Early Treatment Diabetic Retinopathy Study (ETDRS)-like visual acuity testing charts at a testing distance of 4 meters.

Time frame:
12 months
Reported as:
Number · Percentage of participants
Percentage of Participants With Improvement in BCVA
Percentage of participantsRFB002Laser Photocoagulation
Percentage of Participants With Improvement in BCVA74.2968.42
SecondaryEvolution of Mean Change From Baseline in BCVA by Study Visit

Visual acuity (VA) was assessed on the study eye during every study visit using best correction determined from protocol refraction. VA measurements were performed with the patient in a sitting position using Early Treatment Diabetic Retinopathy Study (ETDRS)-like visual acuity testing charts at a testing distance of 4 meters.

Time frame:
Baseline, Months 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12
Reported as:
Mean · letters
Evolution of Mean Change From Baseline in BCVA by Study Visit
lettersRFB002Laser Photocoagulation
Month 1 (n=34,38)4.56 ± 7.381.32 ± 7.99
Month 2 (n=31,38)4.61 ± 6.551.89 ± 8.04
Month 3 (n=33,38)6.24 ± 6.413.11 ± 7.83
Month 4 (n=33,37)6.33 ± 7.402.76 ± 8.66
Month 5 (n=31,37)7.03 ± 8.003.38 ± 8.95
Month 6 (n=33,35)7.61 ± 6.884.11 ± 7.65
Month 7 (n=33,33)7.91 ± 7.163.85 ± 7.97
Month 8 (n=32,34)8.00 ± 7.773.21 ± 7.75
Month 9 (n=32,33)8.44 ± 8.786.00 ± 9.81
Month 10 (n=31,32)7.32 ± 8.175.84 ± 9.14
Month 11 (n=32,32)7.69 ± 8.886.44 ± 8.32
Month 12 (n=32,33)9.41 ± 9.155.79 ± 9.40
SecondaryPercentage of Participants With VA > 73 Letters With Ranibizumab (0.5 mg) vs Laser.

VA score was based on the number of letters read correctly on the Early Treatment Diabetic Retinopathy Study (ETDRS) visual acuity chart assessed at a starting distance of 4 meters.

Time frame:
12 months
Reported as:
Number · Percentage of participants
Percentage of Participants With VA > 73 Letters With Ranibizumab (0.5 mg) vs Laser.
Percentage of participantsRFB002Laser Photocoagulation
Percentage of Participants With VA > 73 Letters With Ranibizumab (0.5 mg) vs Laser.54.2923.68
SecondaryMean Change From Baseline in Central Retinal Thickness (CRT) by Study Visit

CRT was assessed by Optical Coherence Tomography (OCT).

Time frame:
Baseline, Months 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12
Reported as:
Mean · micrometers
Mean Change From Baseline in Central Retinal Thickness (CRT) by Study Visit
micrometersRFB002Laser Photocoagulation
Month 1 (n=33,37)-50.18 ± 62.23-21.86 ± 82.86
Month 2 (n=31,38)-69.52 ± 65.10-14.21 ± 66.95
Month 3 (n=33,37)-80.64 ± 87.06-43.16 ± 89.74
Month 4 (n=33,38)-81.79 ± 92.14-37.66 ± 83.29
Month 5 (n=30,37)-77.77 ± 73.47-28.92 ± 91.51
Month 6 (n=33,34)-93.73 ± 79.42-40.47 ± 100.12
Month 7 (n=33,35)-92.76 ± 79.55-60.94 ± 110.05
Month 8 (n=32,34)-92.41 ± 82.27-64.82 ± 110.05
Month 9 (n=32,34)-81.59 ± 81.38-74.59 ± 112.75
Month 10 (n=31,31)-83.32 ± 81.56-84.39 ± 102.79
Month 11 (n=32,33)-98.03 ± 76.75-94.85 ± 114.67
Month 12 (n=32,33)-76.28 ± 76.56-86.00 ± 115.53
SecondaryPercentage of CRT Change From Baseline by Study Visit

CRT was assessed by Optical Coherence Tomography (OCT).

Time frame:
Baseline, Months 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12
Reported as:
Mean · Percentage change
Percentage of CRT Change From Baseline by Study Visit
Percentage changeRFB002Laser Photocoagulation
Month 1 (n=33,37)-12.06 ± 15.16-3.01 ± 17.52
Month 2 (n=31,38)-15.61 ± 13.90-2.20 ± 15.24
Month 3 (n=33,37)-18.25 ± 17.09-7.97 ± 17.80
Month 4 (n=33,38)-18.00 ± 17.93-6.99 ± 17.18
Month 5 (n=30,37)-18.21 ± 15.68-6.39 ± 19.27
Month 6 (n=33,34)-20.69 ± 15.85-8.55 ± 21.06
Month 7 (n=33,35)-21.11 ± 15.68-12.50 ± 23.05
Month 8 (n=32,34)-21.20 ± 16.43-13.02 ± 20.95
Month 9 (n=32,34)-19.17 ± 17.95-15.68 ± 21.87
Month 10 (n=31,31)-19.55 ± 17.34-17.24 ± 19.63
Month 11 (n=32,33)-22.65 ± 15.85-19.04 ± 22.31
Month 12 (n=32,33)-18.23 ± 16.66-16.59 ± 25.06

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
RFB002—3/39 (7.7%)2/39 (5.1%)
Laser Photocoagulation—2/43 (4.7%)3/43 (7%)
Most frequent serious events
Most frequent serious events
EventRFB002Laser Photocoagulation
Cardiac failure acuteCardiac disorders1/390/43
Cerebral infarctionNervous system disorders1/390/43
Necrosis ischaemicVascular disorders1/390/43
Cardiac failure congestiveCardiac disorders0/391/43
Penile cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/391/43
Most frequent other events
Most frequent other events
EventRFB002Laser Photocoagulation
Cataract operationSurgical and medical procedures0/393/43
PharyngitisInfections and infestations2/390/43

Baseline characteristics

Age, Continuous
Age, Continuous(Years)RFB002Laser PhotocoagulationTotal
Mean61.31 ± 8.9465.47 ± 9.4063.49 ± 9.36
Sex: Female, Male
Sex: Female, Male(Participants)RFB002Laser PhotocoagulationTotal
Female151833
Male242549
08

Study locations

17 sites
  • Novartis Investigative Site
    Malaga, Andalucia 29010, Spain
  • Novartis Investigative Site
    Almería, Andalucía 04009, Spain
  • Novartis Investigative Site
    Cadiz, Andalucía 11009, Spain
  • Novartis Investigative Site
    Hospitalet de Llobregat, Barcelona 08907, Spain
  • Novartis Investigative Site
    Valladolid, Castilla y Leon 47011, Spain
  • Novartis Investigative Site
    Terrassa, Cataluña 08221, Spain
  • Novartis Investigative Site
    Valencia, Comunidad Valenciana 46026, Spain
  • Novartis Investigative Site
    Mallorca, Islas Baleares 07198, Spain
  • Novartis Investigative Site
    La Laguna, Las Palmas de Gran Canaria 38320, Spain
  • Novartis Investigative Site
    Pamplona, Navarra 31080, Spain
  • Novartis Investigative Site
    Barakaldo, Pais Vasco 48903, Spain
  • Novartis Investigative Site
    Barcelona, 08021, Spain
  • Novartis Investigative Site
    Barcelona, 08025, Spain
  • Novartis Investigative Site
    Las Palmas de Gran Canaria, 35016, Spain
  • Novartis Investigative Site
    Madrid, 28002, Spain
  • Novartis Investigative Site
    Madrid, 28035, Spain
  • Novartis Investigative Site
    Madrid, Spain
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Nov 2009, a primary completion of Aug 2012 and a completion of Aug 2012. It does not say whether these dates are actual or estimated.

Results were first posted in Jul 2014, 1 year 11 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
May 11, 2009
First posted
May 13, 2009
Start
Nov 2009
Primary completionActual
Aug 2012
CompletionActual
Aug 2012
Results first posted
Jul 3, 2014
Last update
Mar 3, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 3, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00901186
Responsible party
Sponsor
First posted
May 13, 2009
Start date
Nov 2009
Primary completion
Aug 2012
Completion
Aug 2012
Results posted
Jul 3, 2014
Last update
Mar 3, 2017

Study contacts

Novartis Pharmaceuticals
study director · Novartis Pharmaceuticals
Novartis Pharmaceuticals
study chair · Novartis
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ranibizumab

Start the discussion